Phase A — Understand the business
Lens 1 · Company Overview
IperionX is a pre-revenue critical-materials technology company trying to rebuild a domestic, recycled, low-cost titanium supply chain inside the United States — and, as a second pillar, a domestic source of titanium minerals + heavy rare earths. The thesis in one line: titanium is strategically vital and ~80–90% controlled by China/Russia/Kazakhstan via the 80-year-old, dirty, energy-hungry Kroll process; IperionX claims patented technology that makes titanium powder from 100% scrap, at 40–70% lower cost and >50% lower energy, on US soil.
Two pillars:
- Titanium metals (Virginia "Titanium Manufacturing Campus," Halifax County, VA) — the operating core. Proprietary HAMR™ (Hydrogen Assisted Metallothermic Reduction → titanium powder) and HSPT™ (Hydrogen Sintering & Phase Transformation → near-net-shape parts with claimed wrought-equivalent properties). Transitioned to 24/7 continuous production in the March-2026 quarter; producing ~4.2 t of HAMR powder in March (~50 tpa annualized), targeting ~200 tpa run-rate by end-CY2026. A new GenX™ continuous-HAMR platform is slated for commercial-scale validation in 2026 to drive the next cost-down.
- Titan Critical Minerals Project (Tennessee) — a heavy-mineral-sands deposit in the "Big Sandy Critical Minerals Province" prospective for titanium minerals (ilmenite/rutile), zircon, and heavy rare earths (dysprosium, terbium, yttrium). A DFS released June 2026 models a US$813M post-tax NPV / 39.4% IRR.
Customers (all early-stage, prototype/low-rate): US Army (ground-vehicle parts, fasteners), American Rheinmetall (US$0.3M prototype, 700 components), Ford (~US$11M over 45 months, not yet booked as revenue), Panerai (luxury watch cases), Carver Pump (US$100k Navy). Plus management's claim of "200+ NDA-backed opportunities" and "90+ active customer programs".
Suppliers/feedstock: titanium scrap (290 t transferred at no cost by the US Government; plus market-procured scrap) and, eventually, its own Titan-mined minerals.
Contract structure: the demand side is dominated by US Government cost-reimbursable funding ($47.1M IBAS + $12.7M DPA Title III + up to $99M SBIR Phase III IDIQ) — this is development funding, not recurring product revenue. Commercial offtake is still at the purchase-order/prototype stage. There is no take-or-pay backlog and no recurring revenue base yet.
Lens 2 · Supply Chain
Map upstream → IperionX → end customer, named:
- Upstream feedstock: (a) titanium scrap — sourced from the open market + a US Government transfer of ~290 t at no cost; (b) future mined minerals from the Titan Project (TN) and the just-acquired Covia Camden silica-sand operation (US$3M, mineral rights + stockpiles + mining equipment + rail infrastructure, adjacent to Titan).
- Process chokepoint = IperionX itself. The entire value proposition is that it replaces the upstream chokepoints (Kroll sponge from China/Baoji, Russia/VSMPO, Kazakhstan/UKTMP; the melt/forge steps) with HAMR (powder) + HSPT (part). It is vertically integrating mineral → powder → near-net-shape component in one site.
- Midstream peers / alternative routes it bypasses: ingot/sponge producers Timet, ATI, Howmet, Perryman (US); VSMPO (RU); Baoji (CN); UKTMP (KZ); Toho & Osaka Titanium (JP, high-purity sponge). Powder atomizers (AP&C/GE, Tekna) sit in the legacy $150–250/kg spherical-powder lane IperionX is attacking.
- Equipment: commissioned a six-axis powder-metallurgy press (May 2026) to expand component manufacturing.
- Downstream end customers: US DoD/Army, American Rheinmetall, Ford, Panerai (Richemont), Carver Pump (Navy), plus stated aerospace/defense/space/shipbuilding/consumer-electronics/automotive/additive end markets.
Single-source dependency to mark: the demand and a large share of funding both currently route through the US Government — the chain's most important node is policy, not a private OEM. That is the chain's strength (national-security tailwind) and its concentration risk.
Lens 3 · Competitive Advantages (moats)
Claimed durable edges:
- Process IP / cost moat. HAMR + HSPT acquired/built (incl. the Nov-2024 Breakthrough Titanium Technologies acquisition) with foundational licenses tracing to ARPA-E / University of Utah work. Management targets ~$55/kg powder at first full utilization → ~$29/kg at 1,400 tpa, vs $150–250/kg for atomized Kroll-derived spherical powder. If real at scale, that is a structural cost advantage, not a marketing claim.
- Feedstock flexibility (100% scrap). Kroll cannot run on 100% scrap; HAMR can — a genuine differentiator and the ESG/closed-loop hook (>90% lower CO₂ per IperionX).
- Regulatory / "friend-shoring" moat. US-government validation (Air Force Research Lab, ARPA-E, R&D 100 Award, DPA Title III) plus a national-security mandate to de-risk titanium from China is a policy moat competitors can't easily replicate — the government is literally handing it scrap and milestone cash.
Bargaining power: today, weak — it needs customers to qualify its material (long aerospace/defense qualification cycles) more than they need it, and it needs government cash to fund the build. The bargaining power flips only if/when it is the lowest-cost qualified domestic source at volume.
Moat skeptic's note: "process IP" in metals is historically leaky and slow to defend; the binding constraint is qualification + yield at scale, not a patent. Until 1,400 tpa proves the cost curve, the moat is a claim with government endorsements, not a demonstrated one.
Lens 4 · Segments
No segments.csv data exists (`` empty) and the company is pre-revenue, so there is no revenue-by-segment to break out — n/a for any segment P&L. Structurally there are two reportable pillars:
| Pillar | Stage | Key metric | Source |
|---|
| Titanium Metals (VA) | Early commercial ramp | ~50 tpa now → 200 tpa (end-2026) → 1,400 tpa (mid-2027) → 10,000+ tpa (2030) | |
| Titan Critical Minerals (TN) | DFS complete (Jun-2026), pre-construction | NPV US$813M / IRR 39.4% / capex US$381M / 14-yr life; first production ~Sep-2028 | |
Trend: metals is accelerating operationally (60× capacity vs pilot 12 months prior per management) but not yet financially. The minerals pillar is a separate, capital-intensive mining project years from cash flow.
Phase B — Measure performance
Operating-battery note: IperionX has no revenue, no consensus EPS, and no GAAP earnings to beat or miss. I run Phase B as a pre-revenue ramp + cash-runway read, which is the honest analogue for "measure performance" on a development-stage name.
Lens 5 · Earnings Result (latest print = March-2026 quarter)
- Cash: US$48.2M at 31-Mar-2026, plus US$42.1M remaining obligated-but-undrawn US Government funding.
- Cash trajectory / burn: down from US$79.2M at 30-Sep-2025 to US$48.2M at 31-Mar-2026 — i.e. ~US$31M consumed over two quarters (~US$15M/qtr gross, partly offset by reimbursements).
- FY2026 year-end cash guidance: US$36–40M — implying another ~$8–12M net outflow into June-2026 fiscal year-end and a financing need within ~12 months to fund the 1,400 tpa expansion.
- Revenue: ~$0 booked. Customer receipts at "early inflection point"; Ford (~$11M/45mo) and other POs not yet recognized.
- Cost flag (important): corporate/G&A jumped from ~US$3.3M to ~US$16.2M (~5×) — partly genuine scaling, partly the kind of overhead inflation a skeptic watches.
- Historical net loss: ~−US$21.8M in FY2024, losses growing with the build.
- Market reaction context: the stock is down ~45–55% from its Jan-2026 ATH of $60.11 (ADR) to the ~$28–34 area — the market has de-rated the name hard since the short report and amid dilution fear.
Read: this is a textbook pre-commercial ramp — cash going out, capacity going up, revenue still a rounding error, financing clock ticking. Nothing "beat/missed"; the only number that matters is runway-to-1,400 tpa vs the next raise.
Lens 6 · Earnings Calls / Communications (sentiment trend)
No transcripts/ on disk; sentiment read from letters/quarterlies/releases:
- Consistent, escalating bullish operator tone across the 2026 Letter (Feb), Mar-2026 quarterly (Apr), six-axis-press release (May), and Titan DFS (Jun). Recurring phrases: "fully integrated American titanium supply chain," "lowest-cost," "largest scale," "national security," "24/7 continuous."
- New language in 2026: "GenX™" (next-gen continuous HAMR) and "credibility inflection" framing — management itself concedes 2026 is about proving the model, not revenue.
- What they stopped saying / pivoted: the 2023 "world's largest 100% recycled Ti powder facility by 2025" target has effectively slid — 200 tpa is now an end-2026 goal — a timeline-slippage tell a skeptic will hold them to.
- Defensive posture (Nov-2025): issued a formal "Response to Short Seller Report" leaning on government validation rather than a line-by-line rebuttal — confident in tone, but notably did not itemize Spruce Point's specific allegations.
Trend: tone is uniformly promotional-positive and has not softened despite the share-price collapse — which cuts both ways (conviction vs. promotion).
Lens 7 · Comps
| Company | Type | Note | Source |
|---|
| IperionX (IPX) | Pre-rev Ti tech | Mkt cap ~$0.9B–$1.38B (ADR; varies w/ price) | |
| ATI Inc. | Incumbent Ti/specialty | Profitable; +80% Ti melt capacity by 2025; Airbus/Boeing LTAs | |
| Howmet Aerospace | Incumbent Ti parts | Profitable aero-structures/engines | |
| Perryman | Private US Ti | Defense/implant grade | |
| Timet (PCC) | Incumbent sponge/mill | Global | |
| VSMPO / Baoji / UKTMP / Toho / Osaka Ti | Foreign sponge/ingot | The supply chain IPX targets | |
| MP Materials, USA Rare Earth, Energy Fuels | US critical-materials peers | Closer valuation analogue — pre/early-revenue gov't-backed reshoring names trading on NPV, not earnings | |
- End-market sizing: global titanium powder market ~US$1.2B (2022) → ~$1.66B (2025), growing ~12.5% CAGR to 2030; aerospace/defense ~44–50% of demand. IperionX cites a $4.3B titanium-fastener market as a beachhead.
- The honest comp statement: IperionX trades like an option on a cost-curve + a government mandate, valued on a 2029–2030 EBITDA-multiple basis by its own analysts (one note lifts the 2029 EV/EBITDA from 7× to 8×), not on any current multiple. Bears say that is exactly the problem.
Lens 8 · Stock-Price Catalysts (>5% moves, last ~2–4 yrs as a Nasdaq/ASX name)
- 2024–2025 melt-up → Jan-2026 ATH US$60.11 (ADR): driven by serial US-Government funding awards, 24/7-production milestone, first furnace runs, customer POs, and the broad "critical minerals reshoring" trade.
- 12-Nov-2025: Spruce Point short report → sharp sell-off. Triggered a Levi & Korsinsky securities investigation and recurring ~14% down-days. This is the single biggest negative catalyst on the tape.
- Government-funding headlines repeatedly move it up (e.g. $25M Sep-2025, final $4.6M + 290 t scrap Jan-2026).
- Jun-2026: Titan DFS ($813M NPV) + Covia Camden acquisition — incremental positive catalysts.
Pattern: the market reacts hardest to (1) US-Government funding/validation (up) and (2) credibility/short attacks + dilution fears (down). It is not an earnings-reaction stock (no earnings) — it is a policy-and-credibility stock. That makes it unusually headline-driven and high-beta.
Phase C — Judge people & books
Lens 9 · Management
- CEO / co-founder: Anastasios "Taso" Arima (MD & CEO since Mar-2021; ~5 yr tenure). Greek-born, UWA-educated (Commerce + Engineering). Founded Piedmont Lithium (Nasdaq: PLL) and secured its early funding/Nasdaq listing.
- Skin in the game: Arima owns ~2.5%; director Todd Hannigan ~7.9%; institutions ~43% (BNY Asset Mgmt ~17% largest, FMR/Fidelity ~8.1%). Decent institutional sponsorship for a microcap; founder stake is modest, not controlling.
- Comp: ~US$2.0M/yr, 76% bonus/equity-weighted — incentive-heavy.
- Capital-allocation history: the defining trait is serial equity issuance — shares 69M (FY21) → 135M → 168M → 218M (FY24) ordinary, +215% in three years, plus a ~A$70M (US$46M) placement. Pattern = fund an ambitious build chiefly via dilution + government grants. Bolt-on M&A (Breakthrough Titanium Tech 2024; Covia Camden US$3M 2026) has been small and strategic.
- Archetype: a founder-promoter in the critical-minerals mold — visionary, government-relations-savvy, narrative-strong, dilution-comfortable. This archetype is fit for the early capital-raising stage but is exactly the profile short-sellers target (see Lens 13).
- Red flags (alleged, ): Spruce Point alleged undisclosed Arima-controlled entities (PowerChem Inc., PowerChem Land LLC, GX Technologies LLC) tied to a separate graphene-oxide promotion, and overlap with Piedmont Lithium, which itself faced short-seller promotion allegations. Unproven, but a governance question that belongs on the record.
Lens 10 · Forensic Red Flags
Accounting-risk surface (pre-revenue dev-stage):
- Revenue recognition: minimal — but watch how the Ford ~$11M/45mo and government-reimbursable amounts get recognized once they start; cost-reimbursable government accounting can flatter optics if presented as "funding" near revenue.
- Cash flow vs. earnings: the meaningful divergence Spruce Point flagged is on operating cash flows / "financial reporting issues that appear to affect operating cash flows" — the specific item to verify in the 20-F (not on disk).
- Inventory: Spruce Point noted no inventory on the balance sheet and no inventory purchases through 30-Sep despite production claims — a flag to reconcile against the 24/7-production narrative.
- Capitalized vs. expensed build, G&A: the ~5× G&A jump ($3.3M→$16.2M) and Spruce Point's claimed discrepancies in employee count, capex accounts, and Titan acreage (1,486 claimed vs ~1,349 in county records) are the forensic items.
- Stock-based comp: comp is 76% equity/bonus-weighted — SBC dilution is a real, recurring line.
Regulatory findings (required):
- SEC EDGAR EFTS (LR + AAER): no Litigation Releases and no AAERs naming IperionX in the search window (2021-06-30→2026-06-30).
- Non-SEC enforcement (FTC/DOJ/FDA/CFPB): no material agency enforcement actions surfaced in web search.
- Securities litigation: Levi & Korsinsky announced a shareholder investigation / putative class action (Nov-2025) following the Spruce Point report and price drop. This is plaintiff-bar activity in the wake of a short report — common, early-stage, not an SEC action — but it is a live legal overhang.
- Item 3 Legal Proceedings: the most recent annual report (20-F) is not on disk (`` unavailable) — cannot quote it directly; flag for the next refresh once filings are ingested.
- Net: No SEC/regulatory enforcement found via EDGAR EFTS (LR, AAER) + web as of 2026-06-30, but a short-report-driven securities investigation is open and several financial-reporting discrepancies are alleged (unproven).
Phase D — Project & stress-test
Lens 11 · Forward Projection
There is no current EPS and no reliable consensus EPS (pre-revenue, loss-making), so a three-year EPS ladder would be fabrication — I state the inputs and give a revenue-ramp + cash-need projection instead, every line labeled.
Operating ramp (titanium metals), management targets: ~50 tpa (now) → 200 tpa (end-CY2026) → 1,400 tpa (mid-2027) → 10,000+ tpa (2030).
Illustrative revenue at 1,400 tpa: at a blended realized price in management's $180–400/kg finished-component range, 1,400 t = 1.4M kg →
- Low: 1.4M kg × $180/kg = ~$252M revenue
- High: 1.4M kg × $400/kg = ~$560M revenue
Cost curve: ~$55/kg → ~$29/kg powder at 1,400 tpa; powder ≠ finished part, so gross margin depends on the HSPT part conversion.
Cash / financing: $48.2M cash (Mar-26) + $42.1M undrawn gov't funding; FY26 year-end guide $36–40M; a sizeable equity raise (one source flags a potential ~$50M raise / ~20% dilution at depressed prices) is likely needed within ~12 months to fund the 1,400 tpa expansion.
Titan minerals pillar: NPV US$813M post-tax, IRR 39.4%, capex US$381.3M, first production ~Sep-2028 — a separate multi-hundred-million capex program, i.e. more financing, not less.
Base call: revenue stays immaterial through FY2026; FY2027 is the first year with a chance at >US$50M revenue, contingent on the 1,400 tpa ramp and customer qualification; the equity count keeps rising. (No forecast.ts create per --watchlist rules.)
Lens 12 · Bull vs Bear
Bull case. The US must re-shore titanium — it is on every critical-minerals list, ~80–90% non-US controlled, and irreplaceable in aerospace/defense/space/shipbuilding. IperionX is the best-funded, best-validated domestic challenger with technology the Air Force/ARPA-E/DPA have repeatedly backed with cash and feedstock, a credible 40–70% cost advantage, and the only 100%-scrap route. If the 1,400 tpa expansion (mid-2027) hits the cost curve and even a few of the 90+ customer programs (Ford, Rheinmetall, defense fasteners — a $4.3B beachhead) convert to volume, the company re-rates from "option" to "earnings," and the Titan minerals project ($813M NPV) is a second leg. Government scaffolding de-risks the build that kills most microcaps. Bull price targets cluster A$9.25 (Bell Potter, ASX ords) and US$40–71 (ADR, median ~US$53).
Bear case (2–3 permanent-impairment risks).
- It never out-executes the cost curve at scale. Pilot economics ≠ 1,400 tpa economics; titanium qualification cycles are years; yield/throughput at continuous scale is unproven. If $29/kg slips to $80/kg, the moat evaporates and so does the NPV.
- Dilution compounds the equity to death. +215% shares in 3 yrs and more raises coming for both the VA expansion and the $381M Titan capex — at a depressed price, existing holders are ground down even if the business "works."
- The credibility/governance overhang is real. A live Spruce Point short thesis (70–95% downside scenarios), a securities investigation, alleged undisclosed related entities, and Piedmont-Lithium déjà vu mean the market will demand proof, not promises — capping the multiple.
Pre-mortem (18 months out, thesis broke): the 1,400 tpa expansion slipped to 2028, realized powder prices came in well below the $180–400/kg part-pricing dream, a dilutive raise hit at a low price, a second short report (Spruce Point hinted at one) landed on the cash-flow/inventory discrepancies, and the stock is a sub-$15 ADR with the Titan project mothballed for lack of capex.
Multiples too high? On any current metric, infinitely (no E). On a 2029–2030 basis, the price already bakes in successful execution — so the risk/reward is asymmetric to the downside at ~$0.9B until 1,400 tpa and real revenue de-risk it.
Contrarian view (what the market may be missing): the government-funding + scrap-transfer arrangement is a more durable competitive moat than the market credits — Washington has chosen IperionX as a national-security instrument, which lowers financing cost and raises the strategic-acquisition floor (an ATI/Howmet/defense-prime could buy it). The short report may have over-discounted a name the US government is structurally motivated to see succeed.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case — anchored on the actual Spruce Point thesis:
- The market is oversupplied, not undersupplied. Spruce Point claims the titanium powder market is "already oversupplied with 3.5× more capacity than shipments" — so why will a new high-cost entrant displace the 80-year-entrenched Kroll chain with locked aerospace LTAs (ATI–Airbus/Boeing)? Qualification inertia favors incumbents.
- Revenue is vapor. A Ford contract "estimated ~$11M starting 2025" with no revenue booked, no inventory on the balance sheet, and no inventory purchases through Sep-30. The "90+ customer programs / 200+ NDAs" are unverifiable funnel, not orders.
- Management is the red flag. Heavy overlap with Piedmont Lithium (itself short-seller-targeted as a "promotion"), plus alleged undisclosed Arima-controlled entities (PowerChem, GX Technologies) running a similar "exciting-industrial-tech" playbook. Pattern-matching to promotion.
- Reporting discrepancies. Claimed mismatches in Titan acreage (1,486 vs ~1,349), G&A, employee count, capex accounts, and "issues that appear to affect operating cash flows". An empty office with piled-up packages and a stale annual report on display is the kind of color that fuels a second report (which Spruce Point hinted at).
- Concentration & assumptions for today's price: the valuation needs (a) the cost curve to hold at scale, (b) qualification to convert, (c) financing at non-destructive prices, and (d) the Titan capex to clear — all four must break right. A 20–30% growth disappointment, or one bad raise, takes a large chunk off a name with no earnings to cushion it.
- Downside: Spruce Point's 70–95% scenarios.
Most dangerous competitor bulls underestimate: not another startup — it's incumbent inertia + cheap foreign sponge. If titanium prices stay soft and Kroll capacity is underutilized, the economic case for paying up for domestic powder weakens to a pure national-security subsidy play.
Lens 14 · Management Questions (ordered by information value)
- At 1,400 tpa, what is your audited, fully-loaded cash cost per kg of (a) HAMR powder and (b) a representative HSPT finished part — and what is the bridge from today's cost to that number?
- Of the "90+ customer programs," how many have firm, dollar-denominated purchase orders with delivery schedules, and what total booked revenue do they represent in the next 8 quarters?
- What is your funding plan to cash-flow breakeven — how many more equity raises, at what cumulative dilution, across the VA expansion and the $381M Titan capex?
- Spruce Point alleged discrepancies in operating cash flow, inventory, employee count, capex accounts, and Titan acreage — please reconcile each, line by line.
- Please disclose CEO Arima's involvement in PowerChem Inc., PowerChem Land LLC, and GX Technologies LLC, and any related-party relationship to IperionX.
- What realized price per kg are you actually achieving today on shipped product, versus the $180–400/kg market-pricing range you cite?
- What are the specific qualification milestones and dates for Ford, American Rheinmetall, and your lead defense fastener programs to move from prototype to rate production?
- Is the US redomicile to Delaware / conversion to domestic-filer (10-K) status actually planned, and on what timeline — and what triggers it?
- What is the yield and throughput of the continuous HAMR (GenX™) line at commercial scale, and how does it change the cost curve vs. batch HAMR?
- How much of the $99M SBIR ceiling and remaining $42.1M obligated funding do you realistically expect to draw, and against what milestones?
- What happens to the Titan Project schedule and the $381M capex if you cannot secure project financing / a strategic partner by 2027?
- What is your answer to the "oversupplied powder market" thesis — what share of the $4.3B fastener / aerospace markets can you actually win, and from whom?
- How do you think about strategic M&A interest from ATI / Howmet / a defense prime, and at what stage would you entertain it?
- What are your patent-protection and trade-secret defenses for HAMR/HSPT, and which claims would survive a determined incumbent design-around?
- What is the single assumption that, if wrong, most impairs the equity — and how are you hedging it?